Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront autologous HSCT versus cyclophosphamide followed by mycophenolate mofetil in early diffuse cutaneous systemic sclerosis
NL-OMON52909Phase 3Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2020
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in systemic sclerosis (SSc) comparing Upfront autologous HSCT with Cyclophosphamide followed by mycophenolate mofetil (2 arms). Primary endpoint: Event-free survival. Started Oct 2020; status: recruiting.
02
Drugs
cyclophosphamidemycophenolate mofetilautologous hematopoietic stem cells
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON52909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52909.